The Long View on Drug Shortages
This article was originally published in RPM Report
Media headlines out of a Capitol Hill briefing on oncology drug approvals trumpeted new data showing that FDA is faster in approving new cancer treatments than the European Medicines Agency. The data will certainly surprise those who fault FDA for being too slow. But for actual legislative changes that may affect the oncology market, all the action is at the other end of the life-cycle, where the drug shortage problem is getting the most attention.
You may also be interested in...
The health care reform law dramatically expanded the number of entities eligible to purchase drugs via the federally administered 340B program, while simultaneously increasing the size of the mandatory discounts given to covered entities. Manufacturers are understandably frustrated. Rather than hope for elimination of the program, however, they may be better served working within the system to contain its impact.
The move means Hylton Joffe can focus exclusively on his role as director of the Office of Rare Diseases.
The agency historically has had challenges recruiting experts for its advisory committees. With most everyone working from home during COVID-19, that task was just made easier, 3D Communications’ Jim DiBiasi says.